Results for the substance 13 valent adsorbed conjugated polysaccharide pneumococcal vaccine

The 13-valent adsorbed pneumococcal polysaccharide conjugate vaccine is used to prevent infections caused by 13 different serotypes of the Streptococcus pneumoniae bacterium. It is indicated for protection against invasive pneumococcal diseases such as pneumonia, meningitis, and sepsis, as well as acute otitis media. It is particularly recommended for young children, the elderly, and individuals with chronic conditions or immunosuppression.

This vaccine is a conjugate and adsorbed product, meaning that the capsular polysaccharides of the bacterium are linked to a carrier protein and fixed onto an adjuvant (usually aluminum hydroxide). This technology enhances the immune response, providing more effective protection, especially in children under 2 years old, who have an underdeveloped immune system.

The vaccine is administered via intramuscular injection according to a vaccination schedule established by public health authorities. It is well-tolerated, but mild side effects such as pain at the injection site, fever, fatigue, or irritability may occur. Severe reactions, such as allergic responses, are rare.

Following the recommended vaccination schedule is essential to ensure optimal protection against pneumococcal diseases.